Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Beginning Cash 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: -57.50%

Freeline Therapeutics Holdings Plc Beginning Cash 1 year YoY Change (%) is -57.50% for the Trailing 12 Months (TTM) ending September 30, 2023, a -27.61% change year over year. Beginning Cash is the amount of cash held by a company at the beginning of a specific period. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Freeline Therapeutics Holdings Plc Beginning Cash for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 91.29 M, a -45.06% change year over year.
Freeline Therapeutics Holdings Plc Beginning Cash for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 166.16 M, a 54.71% change year over year.
Freeline Therapeutics Holdings Plc Beginning Cash for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 107.40 M, a 2,529.16% change year over year.
Freeline Therapeutics Holdings Plc Beginning Cash for the Trailing 12 Months (TTM) ending March 31, 2019 was USD 4.08 M, a 91.33% change year over year.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends